Chemicals

Mitsui Chemicals Agrees to Acquire JSR in ¥1.84 Trillion Semiconductor Materials Deal

The transaction would make JSR a consolidated subsidiary and add photoresists and related materials to Mitsui's ICT Solutions portfolio.

Miriam AchterbergNovember 9, 20265 min read0 views
A translucent molecular bridge links a petrochemical complex to a silicon wafer and photoresist containers under cool blue and amber light.

Mitsui Chemicals, Inc. has signed an agreement to acquire JSR Corp., a Tokyo-based developer and manufacturer of semiconductor materials including photoresists, from investment funds managed by JIC Capital, Ltd. The transaction is valued at ¥1.84 trillion ($11.6 billion) including debt and would make JSR a consolidated subsidiary of Mitsui Chemicals.

Mitsui Chemicals will buy all JSR common shares held by JIC PEFJ1 Limited Partnership and JIC PEF1 Limited Partnership, together with Development Bank of Japan Inc. (DBJ), which will invest ¥200 billion ($1.3 billion). The price consists of an equity value of ¥1.3921 trillion ($8.8 billion) and ¥447.9 billion ($2.8 billion) in interest-bearing debt and other items, with the final consideration subject to adjustment at closing. Mitsui Chemicals also expects to acquire JSR's Class A and Class B preferred shares from Mizuho Bank, Ltd. and DBJ for cash; those shares are slated to convert to common shares after closing, while DBJ's common shares will convert to non-voting preferred shares.

The acquisition is intended to support Mitsui Chemicals' "VISION 2030" plan, which combines a specialty chemicals pillar in Life & Healthcare Solutions, Mobility Solutions and ICT Solutions with a Basic & Green Materials (B&GM) pillar centered on petrochemicals. Mitsui Chemicals said JSR's advanced photoresists, customer base in semiconductor and optical fields and global reach make it a core part of its ICT Solutions domain. The company plans to combine its MITSUI PELLICLE products and JSR's advanced photoresists in front-end processes, and its ICROS Tape and thick-film resists in back-end processes. It is targeting annual incremental profit of about ¥40 billion ($253 million) by fiscal year 2035 from growth and cost synergies.

Funding will come from a ¥1.64 trillion ($10.4 billion) bridge loan from Mitsui Chemicals' principal financial institutions and DBJ's ¥200 billion investment. Net debt/EBITDA is expected to temporarily exceed 4x after closing. To protect an "A"-category credit rating, Mitsui Chemicals plans to refinance the bridge loan within one year using bank loans, bonds and equity. It aims to have the equivalent of ¥300 billion ($1.9 billion) recognized as equity by rating agencies, capping common share issuance, including treasury shares, at ¥150 billion ($948 million) and adding ¥300 billion of mezzanine financing, half of which is assumed to count as equity.

Mitsui Chemicals also plans broader portfolio changes. It first said in May 2025 that it would consider splitting off B&GM and will now add its Mobility Solutions business to the scope, aiming to form a polymer science company with an integrated polymer chain spanning upstream petrochemicals and downstream functional polymers. It also plans to become more asset-light in underperforming businesses, improve its cash conversion cycle and sell shareholdings. Mitsui Chemicals also expects benefits representing business value of ¥350 billion ($2.2 billion) or more, together with JSR's ongoing review of its non-core life sciences business, which covers contract research and contract development and manufacturing.

JSR reported revenue of ¥440.7 billion ($2.8 billion), consolidated operating profit of ¥40.5 billion ($256 million) and profit attributable to owners of ¥59.3 billion ($375 million) for the fiscal year ended March 2026. Four JSR affiliates would become specified subsidiaries of Mitsui Chemicals: Inpria Corp. of Corvallis, Ore.; KBI Biopharma, Inc. of Durham, N.C.; JSR North America Holdings, Inc. of Sunnyvale, Calif.; and JSR Life Sciences, LLC of Sunnyvale, Calif.

The transaction is subject to competition-law and foreign-investment approvals in Japan and overseas. Mitsui Chemicals aims to close in the second half of the fiscal year ending March 2028 and expects the impact on results for the fiscal year ending March 2027 to be minor. The company filed a shelf registration for up to ¥150 billion of common shares, effective Nov. 17, 2026 through Nov. 16, 2028, with proceeds to be used for partial repayment of the bridge loan. SMBC Nikko Securities Inc. and Mizuho Securities Co., Ltd. are expected to be primary underwriters.